Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial
Open Access
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Pathology of Peripheral Artery Disease in Patients With Critical Limb IschemiaJACC, 2018
- Editor's Choice – 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)European Journal of Vascular and Endovascular Surgery, 2018
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trialThe Lancet, 2018
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trialThe Lancet, 2018
- Rivaroxaban with or without Aspirin in Stable Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) TrialCanadian Journal of Cardiology, 2017
- 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery DiseaseJACC, 2017
- 2013 ESC guidelines on the management of stable coronary artery diseaseEuropean Heart Journal, 2013
- An International Model to Predict Recurrent Cardiovascular DiseaseThe American Journal of Medicine, 2012
- Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With AtherothrombosisJAMA, 2010